Skip to main content

What the FDA labels say about taking them together

Abatacept and certolizumab

Certolizumab's FDA label of February 24, 2026 names abatacept in its drug interactions section; the abatacept label PlainMeds reads does not name certolizumab. The certolizumab label: “A higher risk of serious infections was also observed in combination use of TNF blockers with abatacept and rituximab.”

Check it at the source: the abatacept FDA label on DailyMed (effective November 13, 2025, E.R. Squibb & Sons, L.L.C.); the certolizumab FDA label on DailyMed (effective February 24, 2026, UCB, Inc.).

What does the abatacept label say about certolizumab?

Abatacept's label (effective November 13, 2025) does not name certolizumab in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (ORENCIA), E.R. Squibb & Sons, L.L.C., effective November 13, 2025 (SPL set 0836c6ac-ee37-5640-2fed-a3185a0b16eb), via openFDA; the full label on DailyMed

What does the certolizumab label say about abatacept?

Certolizumab label, drug interactions

An increased risk of serious infections has been seen in clinical studies of other TNF-blocking agents used in combination with anakinra or abatacept, with no added benefit.

Certolizumab label, warnings and precautions

A higher risk of serious infections was also observed in combination use of TNF blockers with abatacept and rituximab.

Source: FDA drug label (Cimzia), BLA125160 (Ucb Inc), as published by UCB, Inc., effective February 24, 2026 (SPL set b4c2c9dc-a0bb-4d64-a667-a67ebe88392d), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Abatacept generic labelers
0Certolizumab generic labelers
AbataceptCertolizumab
Labeled forRheumatoid arthritisRheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis
Boxed warningNoYes
Pharmacy cost (NADAC)$1,469.23 per mL 125 mg/mL syringe$6,094.02 per syringe 2x200 mg/mL syringe kit
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?